PL3288955T3 - System dostarczania oparty na Bortezomibie - Google Patents
System dostarczania oparty na BortezomibieInfo
- Publication number
- PL3288955T3 PL3288955T3 PL16733715T PL16733715T PL3288955T3 PL 3288955 T3 PL3288955 T3 PL 3288955T3 PL 16733715 T PL16733715 T PL 16733715T PL 16733715 T PL16733715 T PL 16733715T PL 3288955 T3 PL3288955 T3 PL 3288955T3
- Authority
- PL
- Poland
- Prior art keywords
- bortezomib
- delivery system
- based delivery
- delivery
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/695—Silicon compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Ceramic Engineering (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ITRM20150184 | 2015-04-29 | ||
| PCT/IT2016/000111 WO2016174693A1 (en) | 2015-04-29 | 2016-04-29 | Bortezomib-based delivery system |
| EP16733715.3A EP3288955B1 (en) | 2015-04-29 | 2016-04-29 | Bortezomib-based delivery system |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3288955T3 true PL3288955T3 (pl) | 2020-04-30 |
Family
ID=53765345
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL16733715T PL3288955T3 (pl) | 2015-04-29 | 2016-04-29 | System dostarczania oparty na Bortezomibie |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US10239897B2 (pl) |
| EP (1) | EP3288955B1 (pl) |
| CN (1) | CN107660210B (pl) |
| AU (1) | AU2016255738B2 (pl) |
| BR (1) | BR112017023250B1 (pl) |
| CA (1) | CA2985311A1 (pl) |
| DK (1) | DK3288955T3 (pl) |
| ES (1) | ES2762989T3 (pl) |
| HU (1) | HUE047207T2 (pl) |
| PL (1) | PL3288955T3 (pl) |
| PT (1) | PT3288955T (pl) |
| RU (1) | RU2727156C2 (pl) |
| WO (1) | WO2016174693A1 (pl) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108421043B (zh) * | 2018-02-11 | 2021-03-26 | 华东师范大学 | 一种可示踪的硼酸类纳米药物复合物及其制备方法和用途 |
| US11191836B2 (en) * | 2018-06-01 | 2021-12-07 | Tae Life Sciences, Llc | Biodegradable nanocarrier(s) (BPMOs) for neutron capture therapy and methods thereof |
| CN109045272A (zh) * | 2018-08-01 | 2018-12-21 | 厦门市壳聚糖生物科技有限公司 | 一种硼替佐米磷脂复合物及其制备方法与应用 |
| CN108635590B (zh) * | 2018-08-15 | 2021-05-18 | 内蒙古农业大学 | 一种pH响应的多糖–硼替佐米纳米球及其制备方法和应用 |
| CN109439723A (zh) * | 2018-11-30 | 2019-03-08 | 王瑞明 | 一种多层纳米复合粒子的毒性测试方法 |
| US20210317143A9 (en) | 2019-05-20 | 2021-10-14 | Massachusetts Institute Of Technology | Boronic ester prodrugs and uses thereof |
| CN113444288B (zh) * | 2021-06-10 | 2022-06-07 | 南昌工程学院 | 一种具有可逆交联结构的二氧杂硼烷基团修饰钛酸钡及其制备方法 |
| CN115894555B (zh) * | 2022-11-09 | 2025-08-19 | 国科温州研究院(温州生物材料与工程研究所) | 一种基于动态共价化学的脂质前药纳米组装体及其制备方法和应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011116286A2 (en) * | 2010-03-18 | 2011-09-22 | Innopharma, Llc | Stable bortezomib formulations |
| US10023611B2 (en) * | 2013-04-16 | 2018-07-17 | Cipla Limited | Process for the preparation of bortezomib mannitol ester |
-
2016
- 2016-04-29 AU AU2016255738A patent/AU2016255738B2/en not_active Ceased
- 2016-04-29 US US15/570,254 patent/US10239897B2/en active Active
- 2016-04-29 ES ES16733715T patent/ES2762989T3/es active Active
- 2016-04-29 CA CA2985311A patent/CA2985311A1/en not_active Abandoned
- 2016-04-29 PT PT167337153T patent/PT3288955T/pt unknown
- 2016-04-29 PL PL16733715T patent/PL3288955T3/pl unknown
- 2016-04-29 BR BR112017023250-2A patent/BR112017023250B1/pt active IP Right Grant
- 2016-04-29 DK DK16733715.3T patent/DK3288955T3/da active
- 2016-04-29 HU HUE16733715A patent/HUE047207T2/hu unknown
- 2016-04-29 RU RU2017135265A patent/RU2727156C2/ru active
- 2016-04-29 CN CN201680024374.4A patent/CN107660210B/zh active Active
- 2016-04-29 WO PCT/IT2016/000111 patent/WO2016174693A1/en not_active Ceased
- 2016-04-29 EP EP16733715.3A patent/EP3288955B1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN107660210B (zh) | 2020-07-03 |
| EP3288955B1 (en) | 2019-09-18 |
| WO2016174693A1 (en) | 2016-11-03 |
| EP3288955A1 (en) | 2018-03-07 |
| BR112017023250A2 (pt) | 2018-08-07 |
| HK1250370A1 (zh) | 2018-12-14 |
| CN107660210A (zh) | 2018-02-02 |
| AU2016255738A1 (en) | 2017-10-26 |
| CA2985311A1 (en) | 2016-11-03 |
| US10239897B2 (en) | 2019-03-26 |
| RU2017135265A3 (pl) | 2019-08-29 |
| PT3288955T (pt) | 2020-01-06 |
| DK3288955T3 (da) | 2020-01-02 |
| HUE047207T2 (hu) | 2020-04-28 |
| BR112017023250B1 (pt) | 2023-09-26 |
| RU2727156C2 (ru) | 2020-07-21 |
| ES2762989T3 (es) | 2020-05-26 |
| RU2017135265A (ru) | 2019-04-08 |
| AU2016255738B2 (en) | 2020-10-15 |
| US20180127441A1 (en) | 2018-05-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB201802837D0 (en) | Awrosol delivery system | |
| IL254296B (en) | Dosing system | |
| GB201501510D0 (en) | System | |
| GB201517101D0 (en) | Mixed-reality system | |
| GB201507208D0 (en) | Location system | |
| PT3314091T (pt) | Sistema de entrega de reboco | |
| GB201407614D0 (en) | Content delivery system | |
| HUE047207T2 (hu) | Bortezomib alapú adagolórendszer | |
| PT3073021T (pt) | Sistema de conexão | |
| IL247106B (en) | Material delivery system | |
| PL3310230T3 (pl) | System dozownika | |
| GB2559712B (en) | Solid state delivery system | |
| GB201715590D0 (en) | Delivery system | |
| ZA201705600B (en) | Track-module bogie-suspension system | |
| IL246874A0 (en) | drug delivery system | |
| GB201517276D0 (en) | System | |
| PT3379987T (pt) | Sistema de fixação de recipiente | |
| ZA201708627B (en) | Pump system | |
| GB201517654D0 (en) | Object delivery system | |
| GB201514541D0 (en) | System | |
| GB201721699D0 (en) | Delivery system | |
| GB201522636D0 (en) | Delivery system | |
| IL256994A (en) | Transdermal delivery system | |
| IL256995A (en) | Transdermal delivery system | |
| GB201712561D0 (en) | Delivery system |